+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Invokana

  • ID: 4533517
  • Report
  • February 2019
  • Region: Global
  • 30 pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Drug Overview
Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe/Daiichi Sankyo) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism. They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion. Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Invokana : Diabetic nephropathy
Invokana : Diabetes type 2

LIST OF FIGURES
Figure 1: The authors drug assessment summary of Invokana for diabetic nephropathy
Figure 2: The authors drug assessment summary of Invokana for diabetic nephropathy
Figure 3: Invokana sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Invokana for type 2 diabetes – SWOT analysis
Figure 5: The authors drug assessment of Invokana
Figure 6: The authors drug assessment scorecard for Invokana compared to Januvia
Figure 7: Invokana sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
Figure 8: Invokamet sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25

LIST OF TABLES
Table 1: Invokana drug profile
Table 2: Invokana Phase III trial in diabetic nephropathy
Table 3: Invokana for diabetic nephropathy – SWOT analysis
Table 4: Invokana drug profile
Table 5: Overview of pivotal trial data for Invokana in diabetes
Table 6: Key endpoint data from the CANVAS trial program
Table 7: Invokana sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 8: Invokamet sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
Note: Product cover images may vary from those shown
Adroll
adroll